1. Heparin attenuates symptoms and mast cell degranulation induced by AMP nasal provocation 
Dewan Zeng, PhD, Gaetano Prosperini, MD, Cristina Russo, MD, Lucia Spicuzza, MD, Rosella R Cacciola, MD, PhD, Guiseppe U Di Maria, MD, Riccardo Polosa, MD, PhD 
Journal of Allergy and Clinical Immunology 
Volume 114, Issue 2, Pages (August 2004)
DOI: /j.jaci

2. Fig 1
A, Time course of histamine concentrations in NLF after nasal challenge with AMP in placebo (open symbol) or heparin-treated (closed symbol) days in atopic subjects. Data shown are means ± SEMs of histamine concentrations in the concentrated NLF with a concentration factor of 13 (top graph) or the fold increase in histamine concentrations (bottom graph). B, Time course of histamine concentrations in NLF after nasal challenge with AMP in placebo (open symbol) or heparin-treated (closed symbol) days in nonatopic subjects. Data shown are means ± SEMs of histamine concentrations in the concentrated NLF with a concentration factor of 13 (top graph) or the fold increase in histamine concentrations (bottom graph).
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

3. Fig 1
A, Time course of histamine concentrations in NLF after nasal challenge with AMP in placebo (open symbol) or heparin-treated (closed symbol) days in atopic subjects. Data shown are means ± SEMs of histamine concentrations in the concentrated NLF with a concentration factor of 13 (top graph) or the fold increase in histamine concentrations (bottom graph). B, Time course of histamine concentrations in NLF after nasal challenge with AMP in placebo (open symbol) or heparin-treated (closed symbol) days in nonatopic subjects. Data shown are means ± SEMs of histamine concentrations in the concentrated NLF with a concentration factor of 13 (top graph) or the fold increase in histamine concentrations (bottom graph).
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

4. Fig 2
A, Time course of tryptase concentrations in NLF after nasal challenge with AMP in placebo (open symbol) or heparin-treated (closed symbol) days in atopic subjects. Data shown are means ± SEMs of tryptase concentrations in the concentrated NLF with a concentration factor of 13 (top graph) or the fold increase in tryptase concentrations (bottom graph). B, Time course of tryptase concentrations in NLF after nasal challenge with AMP in placebo (open symbol) or heparin-treated (closed symbol) days in nonatopic subjects. Data shown are means ± SEMs of tryptase concentrations in the concentrated NLF with a concentration factor of 13 (top graph) or the fold increase in tryptase concentrations (bottom graph).
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )

5. Fig 2
A, Time course of tryptase concentrations in NLF after nasal challenge with AMP in placebo (open symbol) or heparin-treated (closed symbol) days in atopic subjects. Data shown are means ± SEMs of tryptase concentrations in the concentrated NLF with a concentration factor of 13 (top graph) or the fold increase in tryptase concentrations (bottom graph). B, Time course of tryptase concentrations in NLF after nasal challenge with AMP in placebo (open symbol) or heparin-treated (closed symbol) days in nonatopic subjects. Data shown are means ± SEMs of tryptase concentrations in the concentrated NLF with a concentration factor of 13 (top graph) or the fold increase in tryptase concentrations (bottom graph).
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )